Emerging Techniques and Technologies for Treatment of Solid Tumors
430 likes | 963 Vues
H ARVARD MEDICAL SCHOOL B ETH I SRAEL D EACONESS M EDICAL C ENTER Emerging Techniques and Technologies for Treatment of Solid Tumors Jonathan B. Kruskal, M.D., Ph.D. Director, Abdominal Imaging Challenges for Treating Solid Tumors V Vector engineering Efflux inhibition
Emerging Techniques and Technologies for Treatment of Solid Tumors
E N D
Presentation Transcript
HARVARD MEDICAL SCHOOL BETH ISRAEL DEACONESS MEDICAL CENTER Emerging Techniques and Technologies for Treatment of Solid Tumors Jonathan B. Kruskal, M.D., Ph.D. Director, Abdominal Imaging
Challenges for Treating Solid Tumors V Vector engineering Efflux inhibition Vector delivery
Enhancing Payload Efficacy • Deliver • Deposit • Detain • Destroy
Innovations in Solid Tumor Treatment • Endovascular advances • Vector engineering • Gene & cell-based therapies • Catheter construction • Interstitial treatments • Thermal ablation (RF, MW, cryo, HIFU) • Efflux inhibition • Interstitial pressure & MDR blockade
Enhancing Payload Efficacy • Deliver • Deposit • Detain • Destroy
Conventional delivery ? Enhanced delivery
Vector Delivery • Catheter design • Therapeutic Vectors • Radio-immunotherapy • Vector engineering • Cell delivery therapies • Gene delivery techniques
Catheter & Stent Construction • Drug-eluting stents • Seeking oncological applications • Endovascular in vivo bioengineering • Gene delivery into endothelial cells • Why not take advantage of angiogenesis?
Vector Delivery • Catheter design • Therapeutic Vectors • Radioimmunotherapy • Vector engineering • Cell delivery therapies • Gene delivery techniques
Radioimmunotherapy • Selective Internal Radiation Therapy • 90-Yttrium microspheres (32mm; resin) • Intra-arterial delivery to tumors • Preferential deposition in vascular tissue • Therapeutic dose to tumor, not organ • Greater radiation exposure than XRT • But, lets optimize this technology!
I131-CEA monoclonal antibody • Antibodies target CEA on cell surface • Deliver I131 to surface of tumor cell (& colon) • Are internalization techniques needed? RFA/heat Sonoporation UV light
Vector Engineering avb3 • Immunoliposomes: • Phage display technology • Multi-targeted probes • Tumor receptors: • Proteases, MMP’s & growth factors • VEGF: diagnostic & therapeutic Doxo Gad
Targeting tumor-associated cells: • Tumor-recruited systemic macrophages • Therapeutic macrophage recruitment
Tumor permeability • Sterically-stabilized liposomes
Cell-Based Therapies • Cell transplantation: • Persistent expression by transduced cells • Fibroblasts and dendritic cells • Await techniques for improved targeting • Intrasplenic hepatocytes • Cell recruitment • Adoptive immunotherapy
Cell recruitment • Image-guided MCF delivery • RFA recruits macrophages • Depots for drug and gene delivery
RF-recruited intratumoral macrophages Liposomal Doxorubicin delivery and release
Adoptive immunotherapy: • Lymphokine-activated killer cells • Tumor-infiltrating lymphocytes (TIL’s) aCEA aCEA cDNA
Gene-Based Therapies • Tissue-specific promoters: • VEGF: activated by angiogenesis • Inducible enhancers: • Heat, hypoxia or ultrasound
Inducible enhancers of gene expression Enhancer subunit Promoter subunit
Inducible enhancers of gene expression • Hypoxia enhances gene expression (VEGF) Hypoxia-inducible factors + Enhancer subunit VEGF gene
Inducible promoters of gene expression • Ultrasound induces heat shock protein expression Targeted US results in local heat delivery US waves Promoter subunit activated by HSP What about other local sources of heat?
Enhancing Payload Efficacy • Deliver • Deposit • Detain • Destroy
Enhance Delivery • Drugs to modulate microvascular permeability • Mechanical delivery enhancers
Pretargeting & endoluminal enhancement: • VEGF to increase endothelial pore size • Transient permeability enhancers: vasoactive peptides (IF-b, RMP-7, TNF-a, LT C4) • Platelet activating factor, FGF, Bradykinin • Osmotic endothelial disruption with mannitol • Mechanical enhancement: • RF ablation and electroporesis/iontophoresis
MTC Delivery to Target Tissue/Organ Body Surface Magnetic Field
Magnetic Targeted Carriers Potentiation of effects of RF ablation by iron
Cooperative Therapies • RF recruitment of targetable macrophages • P53 radiation sensitization • Radiation-inducible promoters • Thermally-activated vectors • In vivo electroporation • RF & liposomal chemotherapy
Combined RF/Doxil ChemotherapyDestruction of Blood Supply Immediately after ablation 2 weeks after ablation
In situ activation of expression: • Induce local liberation of contents • Photoactivation, radiation, US or RFA • Heat sensitive (LTS) or neutral liposomes • In situ reduction & redistribution • Sonoporation of liposomes or contrast agents • US induces gene uptake & expression
Biomaterial • (Antibodies) Structural Polymer (US degraded) • Drug or Gene Sonoporation
Local release of gene inside a tumor Liposome
Hepatic ultrasound-delivered Doxorubicin No ultrasound Ultrasound
Hepatic ultrasound-delivered Doxorubicin Liver Tumor No ultrasound Ultrasound
Enhancing Payload Efficacy • Deliver • Deposit • Detain • Destroy
Efflux inhibitors • Pharmacological inhibitors • ATP-dependent membrane pumps • P-glycoprotein MDR pump • Cyclosporin; verapamil • MDR-associated proteins • Mechanical inhibitors • Catheter design
Inhibition of Doxorubicin efflux by Cyclosporin A CX1 human colon cancer cell
Enhancing Payload Efficacy • Deliver • Deposit • Detain • Destroy
Summary • For treatment of solid tumors, a variety of emerging techniques & technologies exist: • Many opportunities available for technical optimization, including combination therapies • In order to progress: • Await good quality peer-reviewed science • Need randomized prospective clinical trials